Research Pipeline

With many potential new therapies currently in clinical trials, our goal is to be the industry leader in specialty care. We remain focused on discovering scientific breakthroughs to address complex, debilitating diseases.

Explore highlights of our research and development pipeline across our four areas of focus.

Items marked with ^ are being developed in collaboration with Regeneron, * are being developed in collaboration with Alnylam®, and ♦ are being developed in collaboration with Principia Biopharma Inc. Items shown with a † denote a Phase 2/3 trial. Items shown with ▼ denote the INN in the US is cemiplimab-rwlc.

Product Candidate	Technology	Phase I	Phase II	Phase III	Current Phase
Immunology
Dupilumab^ Asthma (12 years and older)	mAb				PHASE III
Dupilumab^ Nasal Polyposis	mAb				PHASE III
Dupixent^ Atopic Dermatitis (12-17 years old)	mAb				PHASE III
Dupixent^ Atopic Dermatitis (6-11 years old)	mAb				PHASE III
Dupixent^ Atopic Dermatitis (6 mo - 5 years old)	mAb				PHASE III
Dupilumab^ Asthma (6-11 years old)	mAb				PHASE II
Dupilumab^ Eosinophilic esophagitis	mAb				PHASE II
SAR100842 Systemic Sclerosis	mAb				PHASE II
SAR440340^ Asthma	mAb				PHASE II
SAR440340^ COPD	mAb				PHASE II
Sarilumab^ Polyarticular Juvenile Idiopathic Arthritis	mAb				PHASE II
Sarilumab^ Systemic Juvenile Arthritis	mAb				PHASE II
SAR439794^ Peanut Allergy	mAb				PHASE I
Oncology
Isatuximab Relapsing Refractory Multiple Myeloma	mAb				PHASE III
Cemiplimab^▼ Non-small Cell Lung Cancer	mAb				PHASE III
Cemiplimab^▼ Advanced BCC	mAb				PHASE II
SAR439459 Advanced Solid Tumors	mAb				PHASE I
SAR408701 Solid tumors	mAb				PHASE I
Rare Diseases
Fitusiran* Hemophilia A & B	RNAi				PHASE III
Avalglucosidase alfa Pompe disease, 2nd generation enzyme	protein-based therapy				PHASE III
Venglustat Autosomal Dominant Polycystic Kidney Disease	small molecule				PHASE III
Olipudase Alfa† Acid Sphingomyelinase Deficiency (ASMD)	protein-based therapy				PHASE II
Venglustat Fabry disease	small molecule				PHASE II
Venglustat Parkinson's disease with a GBA mutation	small molecule				PHASE II
Venglustat Gaucher Type 3	small molecule				PHASE II
Multiple Sclerosis
SAR442168♦ Multiple Sclerosis	BTK inhibitor				PHASE I

The agents mentioned here are investigational and have not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency worldwide for the uses under investigation.

In addition to the candidates in clinical development, we are conducting earlier stage research in a range of therapeutic areas including genetic diseases such as cystic fibrosis, spinal muscular atrophy, and Lebers congenital amaurosis type 1. We have several programs in multiple sclerosis with molecules addressing areas of unmet need, using approaches such as immunomodulation, neuroprotection, and remylination.